vTv Therapeutics Q2 net loss widens to $13.1 million, or $1.05 per share
vTv Therapeutics reported second-quarter 2026 results with no revenue in the quarter, and its net loss attributable to shareholders grew to $13.1 million from $6.0 million a year earlier. Higher R&D spending on the Phase 3 CATT1 trial drove the increase, and the company said its cash should fund operations through the anticipated CATT1 topline data readout.
Key points
- Q2 2026 net loss attributable to vTv shareholders was $13.1 million, or $1.05 per share, versus $6.0 million, or $0.92 per share, in Q2 2025.
- R&D expenses rose to $8.8 million from $4.1 million, mainly due to investment in the Phase 3 CATT1 trial.
- Cash and cash equivalents were $86.6 million at June 30, 2026, down from $88.9 million at December 31, 2025.
- Six-month results included $36.8 million of revenue and net income of $11.1 million, or $0.89 per basic share.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.